AR063459A1 - Metodo para administrar un inhibidor de aurora en el tratamiento del cancer - Google Patents
Metodo para administrar un inhibidor de aurora en el tratamiento del cancerInfo
- Publication number
- AR063459A1 AR063459A1 ARP070104888A ARP070104888A AR063459A1 AR 063459 A1 AR063459 A1 AR 063459A1 AR P070104888 A ARP070104888 A AR P070104888A AR P070104888 A ARP070104888 A AR P070104888A AR 063459 A1 AR063459 A1 AR 063459A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- tumors
- pharmaceutically acceptable
- treatment
- managing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
Método pata tratar a un mamífero incluyendo un ser humano, que sufre de un tumor, que comprende administrar el compuesto 1 de la formula A o una sal farmacéuticamente aceptable del mismo a dicho mamífero por infusion intravenosa, caracterizado porque el compuesto 1 es administrado convenientemente empleando calendarios particulares que permiten un tratamiento más eficaz de los tumores. El compuesto 1 de formula A es un inhibidor de Aurora, nombre químico N-{5-[(2R)-2-metoxi-2- feniletanoil]-1,4,5,6-tetrahidro-pirrolo[3,4-c]pirazol-3-il} -4-(4-metilpiperazin-1-il)-benzamida, y el método de preferencia es para el tratamiento de pacientes que tienen tumores solidos o tumores malignos hematopoyéticos. También se proporciona el uso del compuesto 1 o una sal farmacéuticamente aceptable del mismo, y un vehículo o excipiente farmacéuticamente aceptable, en la fabricacion de un medicamento para el tratamiento de tumores como se describio más arriba.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06123440 | 2006-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR063459A1 true AR063459A1 (es) | 2009-01-28 |
Family
ID=38702074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104888A AR063459A1 (es) | 2006-11-03 | 2007-11-02 | Metodo para administrar un inhibidor de aurora en el tratamiento del cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100256160A1 (es) |
| EP (1) | EP2117539B1 (es) |
| JP (1) | JP5547487B2 (es) |
| CN (1) | CN101588800B (es) |
| AR (1) | AR063459A1 (es) |
| AT (1) | ATE479432T1 (es) |
| AU (1) | AU2007316217A1 (es) |
| BR (1) | BRPI0717998A2 (es) |
| CA (1) | CA2668363A1 (es) |
| CL (1) | CL2007003172A1 (es) |
| DE (1) | DE602007008949D1 (es) |
| EA (1) | EA200970444A1 (es) |
| ES (1) | ES2350803T3 (es) |
| MX (1) | MX2009004607A (es) |
| TW (1) | TW200827361A (es) |
| WO (1) | WO2008052931A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2313097B1 (en) | 2008-07-24 | 2013-03-27 | Nerviano Medical Sciences S.r.l. | Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents |
| ES2703739T3 (es) * | 2008-07-24 | 2019-03-12 | Nerviano Medical Sciences Srl | Combinación terapéutica que comprende un inhibidor aurora cinasa y un agente antineoplásico |
| CN105037399B (zh) * | 2014-04-17 | 2017-04-26 | 深圳永泽医药股份有限公司 | 一类Bcr‑Abl双倍体抑制剂及制备方法与用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02004862A (es) * | 1999-11-15 | 2003-01-28 | Pharma Mar Sa | Tratamiento de aplidina para canceres. |
| CN1578773A (zh) * | 2001-09-21 | 2005-02-09 | 雷迪美国治疗公司 | 新三嗪化合物的方法和组合物 |
| US7141568B2 (en) * | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| EP1711188B1 (en) * | 2004-02-06 | 2012-06-06 | Threshold Pharmaceuticals, Inc. | Anti-cancer therapies |
| TW200808311A (en) * | 2006-03-30 | 2008-02-16 | Nerviano Medical Sciences Srl | Use of a kinase inhibitor for the treatment of particular resistant tumors |
-
2007
- 2007-10-25 EP EP07821854A patent/EP2117539B1/en active Active
- 2007-10-25 EA EA200970444A patent/EA200970444A1/ru unknown
- 2007-10-25 AU AU2007316217A patent/AU2007316217A1/en not_active Abandoned
- 2007-10-25 MX MX2009004607A patent/MX2009004607A/es active IP Right Grant
- 2007-10-25 CA CA002668363A patent/CA2668363A1/en not_active Abandoned
- 2007-10-25 US US12/513,290 patent/US20100256160A1/en not_active Abandoned
- 2007-10-25 ES ES07821854T patent/ES2350803T3/es active Active
- 2007-10-25 CN CN2007800405595A patent/CN101588800B/zh not_active Expired - Fee Related
- 2007-10-25 JP JP2009535056A patent/JP5547487B2/ja not_active Expired - Fee Related
- 2007-10-25 WO PCT/EP2007/061491 patent/WO2008052931A1/en active Application Filing
- 2007-10-25 BR BRPI0717998-7A patent/BRPI0717998A2/pt not_active IP Right Cessation
- 2007-10-25 DE DE602007008949T patent/DE602007008949D1/de active Active
- 2007-10-25 AT AT07821854T patent/ATE479432T1/de active
- 2007-10-31 TW TW096140931A patent/TW200827361A/zh unknown
- 2007-11-02 AR ARP070104888A patent/AR063459A1/es not_active Application Discontinuation
- 2007-11-02 CL CL200703172A patent/CL2007003172A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE479432T1 (de) | 2010-09-15 |
| MX2009004607A (es) | 2009-05-22 |
| JP5547487B2 (ja) | 2014-07-16 |
| CA2668363A1 (en) | 2008-05-08 |
| CN101588800B (zh) | 2012-01-04 |
| TW200827361A (en) | 2008-07-01 |
| US20100256160A1 (en) | 2010-10-07 |
| EP2117539A1 (en) | 2009-11-18 |
| EA200970444A1 (ru) | 2009-12-30 |
| BRPI0717998A2 (pt) | 2013-12-03 |
| ES2350803T3 (es) | 2011-01-27 |
| WO2008052931A1 (en) | 2008-05-08 |
| EP2117539B1 (en) | 2010-09-01 |
| DE602007008949D1 (de) | 2010-10-14 |
| CL2007003172A1 (es) | 2008-06-27 |
| CN101588800A (zh) | 2009-11-25 |
| JP2010523470A (ja) | 2010-07-15 |
| AU2007316217A1 (en) | 2008-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR051099A1 (es) | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas | |
| TW200744636A (en) | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| RU2012106620A (ru) | Комбинации и способы введения терапевтических средств и комбинированной терапии | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| WO2001039763A3 (en) | Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors | |
| DOP2005000039A (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| US20150005355A1 (en) | Combination therapy with parp inhibitors | |
| RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
| AR059501A1 (es) | Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor | |
| DE602006017728D1 (de) | Krebsbehandlung mittels fts und 2-deoxyglucose | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| KR960700063A (ko) | 사람 종양 세포내에서의 테모졸로마이드의 강화방법(Potentiation of temozolomide in human tumour cells) | |
| US20150005354A1 (en) | Combination Therapy With Parp Inhibitors | |
| RU2012108439A (ru) | Способы лечения опухолей головного мозга | |
| UY31417A1 (es) | Una composicion farmacéutica y un proceso para dicha composicion farmacéutica | |
| MX2022000430A (es) | Administracion de agonista de sting e inhibidores de puntos de control. | |
| RU2013131241A (ru) | Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака | |
| KR20130118981A (ko) | 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물 | |
| BRPI0508982A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11 | |
| AR063459A1 (es) | Metodo para administrar un inhibidor de aurora en el tratamiento del cancer | |
| RU2015114967A (ru) | Производные ингенола, применяемые для лечения рака | |
| RU2009101026A (ru) | Применение тимозина-альфа-1 для получения лекарственного средства для лечения злокачественной меланомы на iv стадии | |
| AR041947A1 (es) | Uso de acetil-l-carnitina o de una sal farmaceuticamente aceptable de la misma para la preparacion de un medicamento para prevenir y/o tratar las neuropatias perifericas inducidas por la administracion de un agente anticancer que induce neuropatias perifericas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |